Cancer News and Research

Latest Cancer News and Research

Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting

Allos Therapeutics, Inc. today announced that five abstracts, describing FOLOTYN (pralatrexate injection) data across different types of blood cancers, were accepted in the program for this year's 52nd American Society of Hematology (ASH) Annual Meeting to be held December 4-7, 2010, in Orlando, Florida.

20 Nov 2010

PROTOX closes first tranche of investment by Warburg Pincus

Protox Therapeutics Inc., a leader in the development of receptor targeted therapeutic fusion proteins, today announced it has closed the first tranche of the investment by Warburg Pincus. The investment was approved by 100% of the votes cast by shareholders at the recent special shareholders meeting.

20 Nov 2010

USC Norris designated Phase I Clinical Trial Center of Excellence

The USC Norris Comprehensive Cancer Center (USC Norris) has been designated a Phase I Clinical Trial Center of Excellence by global pharmaceutical company Bristol-Myers Squibb Company. The collaboration will bring a number of new phase I clinical trials to USC Norris, and will enable the cancer center's clinical and basic scientists to provide guidance in early phase drug development and trial design.

20 Nov 2010

Evelyn Y. Davis gifts $100,000 to Swedish Medical Center

Swedish Medical Center announced today that it has received an unrestricted $100,000 gift from nationally known shareholder advocate Evelyn Y. Davis and the Evelyn Y. Davis Foundation. Since establishing her Foundation in 1989, Davis – who is from Washington, D.C. – has now made significant donations across the country to leading medical centers, nationally prominent universities, and various arts organizations.

20 Nov 2010

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

Pfizer Inc. announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival when compared to sorafenib, in the study population.

20 Nov 2010

UH physicists study workings of PGK enzyme that may cause Alzheimer's, cancer

University of Houston physicists are using complex computer simulations to illuminate the workings of a crucial protein that, when malfunctioning, may cause Alzheimer's and cancer.

20 Nov 2010

Siemens to unveil Biograph mMR system at RSNA Annual Meeting

At the 96th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), November 28 - December 2 in Chicago, Siemens Healthcare (Booth #822, East Building/Lakeside Center, Hall D) will unveil the Biograph mMR, the world's first integrated whole-body molecular Magnetic Resonance (MR) system with simultaneous data acquisition technology, currently undergoing clinical use testing.

20 Nov 2010

VeriStrat analysis shows patients with advanced NSCLC benefit from dual targeted therapies

Results from the VeriStrat analysis of a phase II trial of first line erlotinib in combination with sorafenib in patients with advanced non-small cell lung cancer were presented today at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets in Cancer Therapeutics being held in Berlin, Germany by Egbert Smit, MD, PhD of the VU Medical Center, Amsterdam, The Netherlands.

20 Nov 2010

NexACT technology improves oral delivery of five small molecule drugs

Apricus Biosciences, Inc., today announced data from animal studies showing that the NexACT technology significantly improved the oral delivery of five small molecule drugs tested, with the best improvements up to 20-fold, in terms of improvement in absorption.

20 Nov 2010

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Acceleron Pharma, Inc., a biopharmaceutical company developing novel protein therapeutics that regulate the growth and development of tissues and cells, including muscle, bone, red blood cells, and vasculature, today announced the presentation of interim results from the first-in-human clinical study of ACE-041 in patients with advanced cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin, Germany.

20 Nov 2010

Researchers develop medical model for regenerating bladders using stem cells

Researchers in the United States have developed a medical model for regenerating bladders using stem cells harvested from a patient's own bone marrow. The research, published in STEM CELLS, is especially relevant for paediatric patients suffering from abnormally developed bladders, but also represents another step towards new organ replacement therapies.

20 Nov 2010

Merck wins third FOSAMAX bellwether trial

Merck & Co., Inc. today said a federal court jury in New York found in its favor in the Graves v. Merck case, rejecting the claims of a Florida woman who blamed her dental and jaw related problems on her FOSAMAX use. With today's verdict, Merck has won three of the first four bellwether cases in the FOSAMAX litigation.

20 Nov 2010

Marshall Edwards receives non-compliance notice from NASDAQ

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel anti-cancer therapeutics, announced today that it was notified on November 16, 2010 by the Listing Qualifications Staff of The NASDAQ Stock Market that, due to the Company's non-compliance with the minimum $10 million stockholders' equity requirement for continued listing on The NASDAQ Global Market, as set forth in Listing Rule 5450(b)(1), the Company's common stock is subject to delisting unless the Company requests a hearing before a NASDAQ Listing Qualifications Panel.

20 Nov 2010

FDA-approved anti-parasite drug blocks Wnt signaling pathway in colon cancer

An old pinworm medicine is a new lead in the search for compounds that block a signaling pathway implicated in colon cancer. The findings, reported by Vanderbilt University Medical Center researchers in the November issue of Nature Chemical Biology, suggest a fresh approach for developing therapeutics that target the pathway.

20 Nov 2010

TTF therapy may increase median survival time in patients with recurrent glioblastoma tumors

Data presented today from a pivotal, phase III randomized clinical trial for patients with recurrent glioblastoma tumors suggest that Tumor Treating Fields (TTF) therapy may increase median survival time and improve quality of life scores compared to best standard of care chemotherapy.

20 Nov 2010

Consuming a variety of fruit reduces lung cancer risk by 23%

Eating five portions of fruit and vegetables per day is one of the means that experts most frequently recommend for preventing cancer. Now, the European EPIC study carried out by researchers from 10 countries has shown that, in the case of lung cancer, the important thing is not just the quantity but also the variety of fruit consumed, which can reduce the risk by up to 23%.

20 Nov 2010

Anavex closes private placement and issued securities

Anavex Life Sciences Corp. announces that it closed a private placement and issued securities to settle debt owed by the Company.

20 Nov 2010

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

The U.S. Food and Drug Administration approved Xgeva (denosumab) on Thursday to help prevent skeletal-related events (SREs) in patients with cancer that has spread (metastasized) and damaged the bone. Skeletal-related events include bone fractures from cancer and bone pain requiring radiation.

19 Nov 2010

Baxter enters definitive agreement to acquire all hemophilia-related assets Archemix

Baxter International Inc. announced today that it has entered into a definitive agreement to acquire all of the hemophilia-related assets of a privately-held biopharmaceutical company, Archemix, and entered into an exclusive license agreement for certain related intellectual property assets.

From Baxter International Inc. 19 Nov 2010

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

FibroGen, Inc., today announced that new data from a phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia will be presented demonstrating that its first-in-class, investigational oral anemia therapy FG-4592 works differently than erythropoiesis stimulating agents (ESAs) to increase hemoglobin.

19 Nov 2010

Cancer News and Research

Latest Cancer News and Research

Allos Therapeutics to present FOLOTYN data for blood cancers at ASH Annual Meeting

PROTOX closes first tranche of investment by Warburg Pincus

USC Norris designated Phase I Clinical Trial Center of Excellence

Evelyn Y. Davis gifts $100,000 to Swedish Medical Center

Pfizer's Phase 3 AXIS 1032 trial for metastatic renal cell carcinoma meets primary endpoint

UH physicists study workings of PGK enzyme that may cause Alzheimer's, cancer

Siemens to unveil Biograph mMR system at RSNA Annual Meeting

VeriStrat analysis shows patients with advanced NSCLC benefit from dual targeted therapies

NexACT technology improves oral delivery of five small molecule drugs

Acceleron presents ACE-041 interim results for advanced cancer at EORTC-NCI-AACR Symposium

Researchers develop medical model for regenerating bladders using stem cells

Merck wins third FOSAMAX bellwether trial

Marshall Edwards receives non-compliance notice from NASDAQ

FDA-approved anti-parasite drug blocks Wnt signaling pathway in colon cancer

TTF therapy may increase median survival time in patients with recurrent glioblastoma tumors

Consuming a variety of fruit reduces lung cancer risk by 23%

Anavex closes private placement and issued securities

Xgeva receives FDA approval for prevention of SREs in patients with bone metastases

Baxter enters definitive agreement to acquire all hemophilia-related assets Archemix

FibroGen to present FG-4592 phase 2a study of patients with stage 3-4 Chronic Kidney Disease and anemia

Understanding the DNA Damage Response in Innate Immunity eBook

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

Newsletters you may be interested in